MicrobiologybioRxivPreprint
Ex Vivo Validation of Six FDA-Approved Non-Receptor Tyrosine Kinase Inhibitors (NRTKIs) as Antivirals to Pandemic and Seasonal Influenza A Viruses
R. Meineke, S. Stelz, M. Busch…·H. Elbahesh
The paper tests six FDA-approved non-receptor tyrosine kinase inhibitors for antiviral activity against influenza A viruses in cell cultures and human lung slices, finding potent inhibition of virus replication.
DOI 10.1101/2022.01.19.476993